Literature DB >> 24338510

Dendritic cells transfected with hepatocellular carcinoma (HCC) total RNA induce specific immune responses against HCC in vitro and in vivo.

B H Xie1, J Y Yang, H P Li, B Zhang, W Chen, B Zhou, B G Peng, L J Liang, Q He.   

Abstract

BACKGROUND: Immunotherapy is an effective method for preventing metastasis and recurrence of carcinoma. Hepatocellular carcinoma (HCC) is a common malignancy with a high rate of recurrence, and has not successfully been introduced to immunotherapy.
METHODS: Peripheral blood mononuclear cells were isolated from whole blood of HCC patients and stimulated to transform into dendritic cells (DCs). These DCs were then transfected with RNA extracted from HepG-2 hepatoma cells to induce expression of specific antigens.
RESULTS: The transfected DCs stimulated T lymphocytes to produce cytotoxic T lymphocytes, which specifically attacked HepG-2 cells. Injection of T lymphocytes from HCC patients and transfected DCs into severe combined immunodeficiency mice limited the growth of HepG-2 tumors.
CONCLUSION: A specific immune response against hepatoma can be generated in vivo by administering DCs transfected with RNA from a specific tumor. This method may have therapeutic application in humans to reduce recurrence of HCC.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24338510     DOI: 10.1007/s12094-013-1145-7

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  27 in total

Review 1.  RNA as a tumor vaccine: a review of the literature.

Authors:  J Saenz-Badillos; S P Amin; R D Granstein
Journal:  Exp Dermatol       Date:  2001-06       Impact factor: 3.960

2.  Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells.

Authors:  D Boczkowski; S K Nair; J H Nam; H K Lyerly; E Gilboa
Journal:  Cancer Res       Date:  2000-02-15       Impact factor: 12.701

3.  Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA.

Authors:  S K Nair; D Boczkowski; M Morse; R I Cumming; H K Lyerly; E Gilboa
Journal:  Nat Biotechnol       Date:  1998-04       Impact factor: 54.908

4.  Human dendritic cells transfected with renal tumor RNA stimulate polyclonal T-cell responses against antigens expressed by primary and metastatic tumors.

Authors:  A Heiser; M A Maurice; D R Yancey; D M Coleman; P Dahm; J Vieweg
Journal:  Cancer Res       Date:  2001-04-15       Impact factor: 12.701

5.  Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostate-specific CTL responses in vitro.

Authors:  A Heiser; P Dahm; D R Yancey; M A Maurice; D Boczkowski; S K Nair; E Gilboa; J Vieweg
Journal:  J Immunol       Date:  2000-05-15       Impact factor: 5.422

6.  Transforming growth factor-beta produced by progressor tumors inhibits, while IL-10 produced by regressor tumors enhances, Langerhans cell migration from skin.

Authors:  G M Halliday; S Le
Journal:  Int Immunol       Date:  2001-09       Impact factor: 4.823

7.  In vitro generation of human CD86+ dendritic cells from CD34+ haematopoietic progenitors by PMA and in serum-free medium.

Authors:  G Ramadan; R E Schmidt; J Schubert
Journal:  Clin Exp Immunol       Date:  2001-08       Impact factor: 4.330

8.  Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells.

Authors:  S K Nair; A Heiser; D Boczkowski; A Majumdar; M Naoe; J S Lebkowski; J Vieweg; E Gilboa
Journal:  Nat Med       Date:  2000-09       Impact factor: 53.440

9.  Generation of dendritic cells from adherent cells of cord blood by culture with granulocyte-macrophage colony-stimulating factor, interleukin-4, and tumor necrosis factor-alpha.

Authors:  Z Zheng; M Takahashi; M Narita; K Toba; A Liu; T Furukawa; T Koike; Y Aizawa
Journal:  J Hematother Stem Cell Res       Date:  2000-08

10.  In vitro generation of dendritic cells from human blood monocytes in experimental conditions compatible for in vivo cell therapy.

Authors:  H Cao; V Vergé; C Baron; C Martinache; A Leon; S Scholl; N C Gorin; J Salamero; S Assari; J Bernard; M Lopez
Journal:  J Hematother Stem Cell Res       Date:  2000-04
View more
  4 in total

Review 1.  Dendritic cells based immunotherapy.

Authors:  Na Shang; Matteo Figini; Junjie Shangguan; Bin Wang; Chong Sun; Liang Pan; Quanhong Ma; Zhuoli Zhang
Journal:  Am J Cancer Res       Date:  2017-10-01       Impact factor: 6.166

Review 2.  Cellular and molecular targets for the immunotherapy of hepatocellular carcinoma.

Authors:  Vikrant Rai; Joe Abdo; Abdullah N Alsuwaidan; Swati Agrawal; Poonam Sharma; Devendra K Agrawal
Journal:  Mol Cell Biochem       Date:  2017-06-07       Impact factor: 3.842

Review 3.  Emergence of immunotherapy as a novel way to treat hepatocellular carcinoma.

Authors:  Naofumi Mukaida; Yasunari Nakamoto
Journal:  World J Gastroenterol       Date:  2018-05-07       Impact factor: 5.742

4.  Breast cancer stem cell RNA-pulsed dendritic cells enhance tumor cell killing by effector T cells.

Authors:  Nuttavut Sumransub; Niphat Jirapongwattana; Pranisa Jamjuntra; Suyanee Thongchot; Thaweesak Chieochansin; Pa-Thai Yenchitsomanus; Peti Thuwajit; Malee Warnnissorn; Pornchai O-Charoenrat; Chanitra Thuwajit
Journal:  Oncol Lett       Date:  2020-01-23       Impact factor: 2.967

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.